1. Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer
- Author
-
Samuel Y Ngan, Michael Jefford, J McKendick, Robert J. Thomas, John Zalcberg, Trevor Leong, Fiona Day, Alvin Milner, J. Di Iulio, Anetta Matera, Michael Michael, and Danny Rischin
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,oesophageal cancer ,Esophageal Neoplasms ,medicine.medical_treatment ,cisplatin ,Docetaxel ,urologic and male genital diseases ,chemoradiotherapy ,Cohort Studies ,Recurrence ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Carcinoma ,Humans ,neoplasms ,Aged ,Cisplatin ,Aged, 80 and over ,Chemotherapy ,business.industry ,organic chemicals ,Cancer ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Survival Analysis ,Surgery ,Radiation therapy ,Clinical Study ,Adenocarcinoma ,Female ,Taxoids ,business ,therapeutics ,Chemoradiotherapy ,medicine.drug - Abstract
Background: Locally advanced oesophageal cancer (LAEC) is associated with poor survival and more effective treatments are needed. The aim of this phase I trial was to assess the maximum tolerated dose (MTD) of a novel weekly docetaxel and cisplatin regimen concurrent with radical radiotherapy. Methods: Patients with unresectable, non-metastatic LAEC were eligible. Treatment comprised docetaxel 15–30 mg m−2 per week and cisplatin 15–30 mg m−2 per week in six planned dose levels (DLs) in 3–6 patient cohorts with 50 Gy radiotherapy in 25 fractions. Maximum tolerated dose was based on defined dose-limiting toxicities (DLTs) during therapy and 2 weeks post therapy. Results: A total of 24 patients were enrolled. There were two DLTs: grade 3 fever in DL1 (docetaxel 15 mg m−2, cisplatin 15 mg m−2) and grade 3 nausea in DL2 (20 mg m−2, 15 mg m−2). These DLs were each expanded to six patients without further DLTs. The most common acute toxicity was grade 3 radiation oesophagitis (37.5%). There were no grade 4 toxicities, and haematologic toxicity was minimal. Cisplatin and docetaxel dose intensity was 100% at the highest dose level (DL6). A MTD was not reached in this trial. Tumour overall response rate was 50% (33% complete, 17% partial). Conclusion: Cisplatin and docetaxel each 30 mg m−2 per week concurrent with 50 Gy radiotherapy is recommended for use in phase II clinical trials in oesophageal cancer.
- Published
- 2010